ICICI Direct: Jubilant Life’s Steady Q2 Numbers Despite Covid-19 Related Challenges
A technician prepares a sample inside a laboratory. (Photographer: Anthony Kwan/Bloomberg)

ICICI Direct: Jubilant Life’s Steady Q2 Numbers Despite Covid-19 Related Challenges


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Jubilant Life Sciences Ltd.’s Q2 results were almost in-line with our estimates.

Revenues grew 4.8% YoY to Rs 2375 crore. Pharma business grew 4.4% YoY to Rs 1,516 crore led by growth in contract manufacturing organisation and generics.

Life science ingredients revenues also grew 4.4% YoY to Rs 786 crore on good demand and improved pricing of select products.

Ebitda margins stayed flattish (down 20 basis points YoY) at 20.5% with lower other expenses being offset by lower gross margins. Ebitda grew 3.8% YoY to Rs 486 crore.

Click on the attachment to read the full report:

ICICI Direct Jubilant Life Q2FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.